MIRA PHARMACEUTICALS, INC.

MIRA Pharmaceuticals reported a net loss of $1.2 million for the three months ended June 30, 2026, and $2.4 million for the six months, an improvement compared to the prior year. However, the company faces significant liquidity challenges, with cash decreasing to $3.6 million and a "going concern" warning due to insufficient funds for the next 12 months. Research and development expenses increased to $1.2 million for the six-month period, while general and administrative expenses decreased. The company continues to advance its clinical pipeline, including Ketamir-2, MIRA-55, and SKNY-1, and holds an equity investment in Telomir Pharmaceuticals.

MIRA Pharmaceuticals announced positive toxicokinetic findings from a 7-day repeated-dose study of SKNY-1 in Beagle dogs. SKNY-1 is an investigational oral drug candidate for obesity designed to preserve lean body mass. The study showed rapid oral absorption, dose-dependent systemic exposure, and systemic accumulation, which de-risks dose selection. These findings support the advancement of SKNY-1 toward GLP toxicology studies required for IND-enabling development.

Mira Pharmaceuticals, Inc. received a letter from Nasdaq on July 27, 2026, indicating non-compliance with the minimum bid price requirement. The company's common stock failed to maintain a closing bid price of at least $1 for 30 consecutive business days, ending July 24, 2026. Mira Pharmaceuticals has been granted 180 calendar days, until January 25, 2027, to regain compliance by achieving a $1 bid price for at least ten consecutive business days. The letter does not result in immediate delisting, and the company plans to monitor its stock and consider options to address the deficiency.

MIRA Pharmaceuticals, Inc. announced its Annual Meeting of Shareholders will be held virtually on September 11, 2026. Shareholders will vote on the election of five directors, the ratification of Salberg & Company, P.A. as the independent registered public accounting firm for fiscal year 2026, and a proposal to adjourn the meeting if necessary. The Board of Directors recommends voting "FOR" all proposals.

MIRA Pharmaceuticals announced positive results from preclinical studies evaluating optimized oral formulations of MIRA-55, its non-opioid drug candidate for chronic inflammatory pain. The company selected a lead formulation demonstrating favorable oral bioavailability, sustained systemic exposure, and reproducible distribution into both brain and liver tissue. These findings strengthen MIRA-55's development profile, building on previous studies that showed it normalized pain and reduced inflammation, outperforming injected morphine, and exhibited a differentiated pharmacological profile from THC.

MIRA Pharmaceuticals announced positive preclinical study results for SKNY-1, its oral drug candidate for obesity and addiction-related disorders. The studies demonstrated favorable oral bioavailability, reproducible systemic exposure, robust brain penetration, and substantial liver exposure, supporting potential once-daily oral dosing. These findings strengthen SKNY-1's development profile, complementing previous efficacy studies that showed reductions in body weight and attenuation of compulsive behaviors without anxiety-related side effects.

MIRA Pharmaceuticals announced new preclinical data for Mira-55, its cannabinoid analog in development for chronic inflammatory pain. The data revealed a differentiated mechanism of action and anxiolytic activity compared to THC, without its known liabilities like psychoactivity and central nervous system side effects. Mira-55 did not cause locomotor suppression or catalepsy and showed a distinct pharmacological mechanism for its effects. These positive findings support the continued advancement of Mira-55 towards an Investigational New Drug (IND) submission for chronic inflammatory pain.

MIRA Pharmaceuticals, Inc. announced the submission of a Phase 2a clinical trial protocol to the U.S. Food and Drug Administration (FDA) for Ketamir-2, its proprietary oral NMDA receptor modulator, to treat chemotherapy-induced peripheral neuropathy (CIPN). The company also received an acknowledgment of receipt from the FDA, confirming acceptance of the submission. This randomized, double-blind, placebo-controlled study aims to evaluate the safety, tolerability, and dose-response efficacy of Ketamir-2 in patients with moderate-to-severe persistent CIPN, addressing a significant unmet medical need.

Mira Pharmaceuticals, Inc. announced the departure of Alan Weichselbaum as Chief Financial Officer, effective June 6, 2026. His departure was not due to any disagreement with the company. Concurrently, the board appointed Andriy Mushak as the company's fractional Chief Financial Officer, effective June 6, 2026. Mr. Mushak, a CPA with over 20 years of experience, will provide services through LMAM Consulting Group, LLC for $6,000 per month.

MIRA Pharmaceuticals, Inc. entered into an Amended and Restated Exclusive License Agreement with MIRALOGX LLC, securing worldwide exclusive rights to its MIRA-55 and SKNY-1 development programs. This agreement grants MIRA global rights to develop, manufacture, commercialize, and sublicense products covered by the licensed intellectual property, along with intellectual property enforcement rights. The amendment consolidates the company's IP portfolio and establishes a unified global rights structure across its core therapeutic assets, without materially changing the existing economic terms.